# Meng Mou Biology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/meng-mou-biology

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Latest round: Angel (Sep 18, 2023)
- Investors on record: 1

## About

Founded in 2023 and based in Chengdu, China, Moucellion (Chengdu) Biotechnology Co., Ltd., dba Meng Mou Biology and Moucellion, is a biotech company that focuses on developing drugs for degenerative eye diseases. In September 2023, the firm raised angel funding from new investor Zhongguancun Development Venture. As of 2023, the company has established a research and development, process development and quality management team of dozens of people. It has cooperated with Beijing Tongren Hospital affiliated to Capital Medical University and Beijing Eye Institute. In January 2026, Meng Mou Biology closed Pre-A1 funding from new investors Future New Intelligence, IDG Capital and returning investor Zhongguancun Development Venture.

The company has technologies such as in vitro induced reprogramming and in vitro induced differentiation of induced pluripotent stem cells (iPSC) and AAV vector optimization. It is committed to using stem cells and gene therapies to treat eye diseases.

The company generates revenue from providing stem cells and gene therapies to treat eye diseases.

## Funding rounds

- Angel, Sep 18, 2023 — Zhongguancun Development Venture

## Investors

- Zhongguancun Development Venture (https://capitalatlas.ai/funds/zhongguancun-development-venture) — Angel